### PATENT COOPERATION TREATY

	REC'D	1	6	DEC	2005
	WIPO				PCT
PC	77				

rioni ale
INTERNATIONAL SEARCHING AUTHORITY

To:

WALTER R. BROOKHART							
SHOOK, HARDY & BACON L.L.P.		•					
JPMORGAN CHASE TOWER 600 TRAVIS, SUITE 1600		WRITTEN OPINION OF THE					
HOUSTON, TX 77002-2911		INTERNATIONAL SEARCHING AUTHORITY					
		,					
· · .		,	(PCT Rule 43bis.1)				
		Deta of mailing					
•		Date of mailing (day/month/year)	12 DEC 2005				
Applicant's or agent's file reference		FOR FURTHER	ACTION	7			
SLRE.103401/			See paragraph 2 below				
International application No.	International filing date	(day/month/year)	Priority date (day/month/year)	$\dashv$			
				ı			
PCT/US04/26851 International Patent Classification (IPC) of	18 August 2004 (18.08.2 or both national classificat		22 August 2003 (22.08.2003)	$\dashv$			
IPC(7): A01N 37/10, 43/12, 43/38, 43/90 Applicant	and US Cl.: 504/241, 284	, 297, 321, 323		$\dashv$			
Applicant		•					
STOLLER ENTERPRISES, INC.			<u></u>				
				$\neg$			
1. This opinion contains indications rela	iting to the following item	ıs:					
Box No. I Basis of the	opinion						
Box No. II Priority							
	hannet of animien with re-	and to movelty invo	ntive stan and industrial applicability				
	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
Box No. IV Lack of unity of invention							
	p. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
Box No. VI Certain documents cited							
Box No. VII Certain defects in the international application							
Box No. VIII Certain obse	ervations on the internation	nal application					
2. FURTHER ACTION							
International Preliminary Examining	g Authority ("IPEA") ex- he IPEA and the chosen I	cept that this does PEA has notified the	be considered to be a written opinion of the not apply where the applicant chooses an le International Bureau under Rule 66.1bis(b) exed.				
If this opinion is, as provided above, IPEA a written reply together, where of Form PCT/ISA/220 or before the e. For further options, see Form PCT/IS.	appropriate, with amenda xpiration of 22 months fro	ments, before the ex	PEA, the applicant is invited to submit to the piration of 3 months from the date of mailing whichever expires later.				
3. For further details, see notes to Form	PCT/ISA/220.						
Name and mailing address of the ISA/ US	Date of complet	tion of this opinion	Authorized officer	$\vec{\Box}$			
Mail Stop PCT, Attn: ISA/US		005 (23.11.2005)	S. Mark Clardy	1.			
Commissioner for Patents P.O. Box 1450	25 November 20	003 (23.11.2003)	).///www./or	4)			
Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201			Telephone No. 571-272-1600	1			
Pausing (C 1901 - 1771 - 1774 - 1774)			V /14				

Form PCT/ISA/237 (cover sheet) (April 2005)

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

Box No. I Basis of this opinion
1. With regard to the language, this opinion has been established on the basis of:  the international application in the language in which it was filed  a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
a. type of material  a sequence listing  table(s) related to the sequence listing
b. format of material on paper in electronic form
c. time of filing/furnishing  contained in the international application as filed.  filed together with the international application in electronic form.  furnished subsequently to this Authority for the purposes of search.
In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
Additional comments:

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International az ilication No – PCT/US04/268 A

Box No. V	Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial
	applicability; citations and explanations supporting such statement

# 1. Statement Novelty (N) Claims 1-77 Claims NONE NO Inventive step (IS) Claims NONE YES Claims 1-77 NO Industrial applicability (IA) Claims 1-77 YES Claims NONE NO

### 2. Citations and explanations:

Claims 1-77 lack an inventive step under PCT Article 33(3) as being obvious over Coenen et al. (*Trends in Plant Science*. 2(9):351-356), Mohr et al. (*Plant Physiology*. P. 383-408), Bernier et al (*The Plant Cell*. 5:1147-1155), and Lin et al (US 6,361,999).

Coenen et al teach that auxin-cytokin interactions in plants control many aspects of growth and differentiation (abstract) and that increases in one affect the concentration of the other (p 351-352; Figure 2). The two hormones affect cell cycle control (p. 353-354).

Mohr et al teach the effects of various known plant hormones including auxin (p. 386-389), gibberellins (389-393), and cytokinins (393-395), among others. Each of these is involved in growth characteristics of plants such as growth of roots, internode length, top growth, and plant structure.

Bernier et al teach that, in addition to their effects on plant growth, cytokinin and auxin each have an effect on flowering (p. 1149-1150), thus control of these two hormones would have a controlling effect on flowering, as well as plant growth characteristics.

Lin et al teach the utility of applying analogs (see figures 2-7 and columns 3-4) of plant hormones such as auxin and cytokinins (col 1) to plants (including seeds: col 6, lines 65-67) for controlling plant growth. The effects of varying the ratio of cytokinin and auxin in potato and tobacco is also discussed (columns 8-9).

One of ordinary skill in the art would be motivated to combine these references in order to determine the known effects of plant hormones, in particular auxin and cytokinin, and how they interact to affect plant growth and physiology.

Thus it would have been *prima facie* obvious to the ordinary artisan at the time the invention was made to have applied plant hormones such as auxins, cytokinins, and gibberellins to plants because the prior art discloses that exogenous application of these hormones may be used to control various aspects of plant growth, including top growth, internode length, plant structure, and flowering. Determination of appropriate application rates is within the skill level of the ordinary artisan.

Claims 1-77 meet the criteria set out in PCT Article 33(4), and thus possess industrial applicability because the subject matter claimed can be made or used in industry.

Form PCT/ISA/237 (Box No. V) (April 2005)